JPMorgan (JPM): 15 Times Earnings, 4.6% Off Its High

JPMorgan trades around $349.67 as I write this, 4.6% below the 52-week high of $366 it set earlier this year and 26% above the low of $276. The reflex reaction to a bank stock this close to its own high is the same one every time: too big, already priced in. That reasoning skips a step. A high price and a rich price are different things, and the only way to tell them apart is to check what earnings did while the stock climbed.

My view: JPMorgan earned its way to this price more than it borrowed its way there. The trailing multiple of 15.0 sits above the five-year average of 11.9, so the stock is not cheap against its own history. The case for owning it rests on guidance that has been rising, rather than on a story that needs the next quarter to bail it out.

What management changed in July

With second-quarter results, JPMorgan lifted its full-year net interest income outlook, and the company’s own release attributed the increase to stronger loan and deposit growth than it had assumed a quarter earlier. Banks rarely raise a number they might have to walk back a quarter later, so the revision carries more weight than a single beat-and-raise headline usually does. The backdrop makes it more interesting still: the Federal Reserve raised its policy rate in mid-September rather than cutting it, which is the setting where net interest income was widely expected to compress, not expand. Loan and deposit growth absorbed that pressure instead.

The quarter itself

Revenue for the quarter that ended June 30 came to $52.9 billion, up 18% from a year earlier and 6% sequentially, putting the trailing four-quarter run rate at $211.4 billion. Full-year 2025 revenue was $181.8 billion, up 7% from $169.4 billion in 2024, and net income for the year came to $57.0 billion, a net margin of 31%. Trailing earnings per share sit at $23.34.

I want to be careful with how much credit trading and investment-banking fees deserve in a quarter like this one. Those lines move with market activity and are the least repeatable part of the mix. The steadier part of the case is deposits, lending and fee income growing together, which is closer to what the net-interest-income guidance raise is actually describing.

Where the multiple sits against its own history

15.0 times trailing earnings compares with a five-year average of 11.9, so JPMorgan is trading at a real premium to where it has typically changed hands. The forward multiple is 14.9, on consensus for $23.49 of forward earnings per share, which is only 1% above the trailing $23.34.

That is a small gap between what the stock earns now and what the market expects it to earn a year from now, and it matters.

Unlike a growth stock where the forward multiple prices in an acceleration, JPMorgan’s forward and trailing earnings are close together, which tells me the market is not betting on a big earnings jump from here. It is paying up for consistency and size, and consistency is a real thing to pay for in banking, where the alternative is a regional lender with a fraction of the deposit base and none of the trading revenue to smooth out a weak lending quarter.

Metric	JPMorgan now	Five-year average
P/E (trailing)	15.0	11.9
P/E (forward)	14.9	n/a
Price/book	2.7	1.9
Price/sales	4.7	3.7

Size is an advantage in a hard year, not always

A regional-bank stress episode in recent years pushed deposits toward the largest, most diversified institutions almost by default, since a depositor worried about a bank’s balance sheet has an easy alternative in one with a trillion-plus in assets and a diversified fee business layered on top of lending. JPMorgan does not have to work for that flow every quarter. It is a real structural tailwind that a smaller regional competitor does not get to use. I made a related point about bank stocks after the rate-cut turn: scale alone is not a thesis; it changes what a bank has to get right to keep growing, and JPMorgan gets to be selective about credit quality in a way a smaller lender chasing growth cannot.

What the sell side and the quant score think

15 analysts cover the stock, and 67% rate it a buy. The average price target is $385, 10% above the current price, though the low target of $340 is actually -3% below where shares sit today, so the range of opinion is wider than the average alone suggests. Short interest is a low 1.0% of the float.

Our own quant score moved from a D to a C over the period covered by the data, an improvement that lines up with the guidance raise rather than contradicting it. The stock’s last earnings-day move was +2.5%, close to its average earnings-day move of 2.4%, which tells me the July report did not surprise the market as much as the guidance raise itself did in the weeks that followed.

The counter-case: rates cut both ways

Here is the specific way this could go wrong. The September rate increase helps net interest margin on new loans, but it also raises the bar for the credit quality of JPMorgan’s existing book, particularly in commercial real estate and consumer lending, where a higher-for-longer rate environment increases the odds of a borrower falling behind. JPMorgan has historically reserved conservatively against exactly this risk, which is part of why its multiple carries a premium, but conservative reserving is a judgment call that gets tested only when a credit cycle actually turns. I would treat a sustained rise in net charge-offs, not a single quarter’s number, as the signal that the premium multiple was too generous.

The dividend, at $6.00 a year and a yield of 1.72%, is a secondary part of the return here. It is well covered by earnings, but it is not the reason to own or avoid the stock at this price. I use the same low-yield, well-covered framing when I look at Bank of America’s own rate bet; the dividend rarely decides these trades either way.

What makes JPMorgan different from a regional lender

It is worth being specific about why size actually matters here, rather than treating it as a vague label. JPMorgan runs four large businesses under one roof: consumer banking, commercial banking, a global investment bank, and an asset and wealth management arm. In a quarter where consumer lending softens, the investment bank can carry the result if markets are active; in a quarter where markets are quiet, steady deposit and loan growth in consumer and commercial banking cushions the miss. A single-line regional lender does not have that internal offset. When its core lending book weakens, there is no second or third business to lean on while it works through the cycle.

That diversification shows up in the numbers as smoother earnings, not necessarily faster growth. JPMorgan’s full-year revenue growth of 7% is not a standout figure next to a growth stock, and I would not pretend otherwise. What the diversification buys is a lower chance of a single bad segment sinking the whole quarter, which is precisely the kind of protection that becomes valuable when nobody quite knows which way a credit cycle is about to turn. Paying a premium multiple for that protection is a reasonable trade as long as the premium stays proportional to the earnings stability, and right now I think it roughly does, though not with much room to spare.

The part of this trade that has nothing to do with JPMorgan

Every dollar allocated to megabank stability is a dollar not allocated somewhere with more upside if the credit cycle turns out fine. That opportunity cost is real and easy to forget when a stock is compounding steadily. A reader choosing JPMorgan over a smaller, faster-growing regional bank is implicitly saying the insurance is worth more than the extra growth, and that is a defensible view in a year when the Fed just raised rates rather than cut them, but it is a view, not a fact, and it is worth being honest with yourself about which one you are actually making before buying the stock for its size alone.

What I would watch into the next quarter

Owning a bank within a few points of its own high is reasonable when earnings and guidance are moving the same direction the price is, which is the case here for now. I would want to see net interest income actually land at or above the raised ~$105.5 billion full-year figure management pointed to in July, not just the guidance holding steady, before treating the current multiple as fully earned rather than partly hopeful. If a future quarter shows net interest income undershooting that number while credit costs tick up at the same time, that combination, not the trailing P/E alone, is what would change my mind.

Analysis and opinion only, not investment advice. Figures come from JPMorgan’s second-quarter 2026 results, filed on SEC EDGAR, and coverage of the guidance raise by CNBC; valuation multiples and price targets are approximate and were checked on September 18, 2026.